• Tue news: Pfizer explores sale of hospital drugs unit. FDA declines full approval of Ocaliva. AZ better than expected Q3 results. Pfizer, Lilly telehealth platforms draw scrutiny. 23andMe cutting lays off 40%. See more on our front page

"Wherever Novartis does business we are committed to the same high standards of ethical business???

anonymous

Guest
do you agree with this statement by Novartis?

"Wherever Novartis does business we are committed to the same high standards of ethical business conduct and regulatory compliance," the spokesman said. "We take any allegation of misconduct extremely seriously and thoroughly review all reports."
 




do you agree with this statement by Novartis?

"Wherever Novartis does business we are committed to the same high standards of ethical business conduct and regulatory compliance," the spokesman said. "We take any allegation of misconduct extremely seriously and thoroughly review all reports."

Perhaps the standards of ethical business conduct are not high enough?
If allegations are taken seriously, how seriously are attempts made to prevent business conduct that does not meet high ethical standards?
 




do you agree with this statement by Novartis?

"Wherever Novartis does business we are committed to the same high standards of ethical business conduct and regulatory compliance," the spokesman said. "We take any allegation of misconduct extremely seriously and thoroughly review all reports."


The BPO says it all about the organization. They tell the employees the BPO is to help identify and fix problems. It is beneficial for the employee to report issues. In Reality the BPO is to protect the company from lawsuits by their employees. I don't think this is ethical business conduct
 




The BPO says it all about the organization. They tell the employees the BPO is to help identify and fix problems. It is beneficial for the employee to report issues. In Reality the BPO is to protect the company from lawsuits by their employees. I don't think this is ethical business conduct

since when is survival behavior unethical?
 








Unethical is when you promote the BPO to your employees as "a help" for the employee when in reality it is in place for the company. If you don't believe this you are conned like many others.

100% true. BPO does not protect the person reporting an issue. They are only protecting the company's liability to see how much the could be sued for. If you have a real issue, hire an attorney, threaten hr and actually get a settlement. BPO will not "solve" any issue either.
 




do you agree with this statement by Novartis?

"Wherever Novartis does business we are committed to the same high standards of ethical business conduct and regulatory compliance," the spokesman said. "We take any allegation of misconduct extremely seriously and thoroughly review all reports."

Are you kidding!?? Novartis and ethical don’t belong in the same universe.
 








Are you kidding!?? Novartis and ethical don’t belong in the same universe.


A lady exec reported an issue with non FDA compliant manufacturing to BPO, aligned with all the glossy corporate governance & speak up brochures that Novartis distributes and waves around as a surrogate for real ethics.

Ada Damla Demir found out very quickly that the novartis kool aid was poisoned

https://www.law.com/newyorklawjourn...e-saves-pharma-employees-whistleblower-claim/

So who isc going to report any thing to BPO or their boss now?
 
Last edited by a moderator:




A lady exec reported an issue with non FDA compliant manufacturing to BPO, aligned with all the glossy corporate governance & speak up brochures that Novartis distributes and waves around as a surrogate for real ethics.

Ada Damla Demir found out very quickly that the novartis kool aid was poisoned

https://www.law.com/newyorklawjourn...e-saves-pharma-employees-whistleblower-claim/

So who isc going to report any thing to BPO or their boss now?

Here is a link to the decision that doesn’t require you to register https://law.justia.com/cases/new-york/appellate-division-first-department/2017/4952-150954-15.html